Category: Sanofi
-
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
•
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Published Feb 22, 2025 • 10 minute…
-
Sanofi MS drug tolebrutinib misses goal in relapsing disease trials By Reuters
•
By Ludwig Berger (Reuters) – Sanofi Nasdaq:NASDAQ:NASDAQ:MSN’S most advanced multiple sclerosis drug failed to meet the main goal of two late-stage trials to treat recurrent forms of the disease, dimming the prospects for a broad class of drugs. The French drugmaker said on Monday that two phase 3 trials showed…
-
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million By Reuters
•
Written by Brendan Pearson (Reuters) – A Hawaii judge on Tuesday ordered Bristol-Myers (NYSE:) Squibb Inc Sanofi (NASDAQ:) to pay more than $916 million to the state for failing to warn nonwhite patients about health risks from the blood-thinner Plavix, up from a previous judgment of $834 million. The ruling…
-
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million By Reuters
•
Written by Brendan Pearson (Reuters) – A Hawaii judge on Tuesday ordered Bristol-Myers (NYSE:) Squibb Inc Sanofi (NASDAQ:) to pay more than $916 million to the state for failing to warn nonwhite patients about health risks from the blood-thinner Plavix, up from a previous judgment of $834 million. The ruling…